What is the clinical significance of an MCHC of 31.6 g/dL and what further evaluation or management is recommended?

MCHC of 31.6 g/dL: Clinical Significance and Management

An MCHC of 31.6 g/dL is below the normal range (typically 32-36 g/dL) and suggests hypochromic anemia, most commonly iron deficiency, requiring immediate evaluation of iron status and investigation for underlying causes, particularly gastrointestinal blood loss in men and post-menopausal women.

Immediate Diagnostic Workup

Your first step is to confirm iron deficiency with:

• Serum ferritin - the most powerful diagnostic test. A level <12 μg/dL is diagnostic of iron deficiency 1
• Mean corpuscular volume (MCV) - expect microcytosis (MCV <80 fL) in iron deficiency
• Complete blood count - assess hemoglobin level and red cell distribution width (RDW)
• Hemoglobin level - define anemia using your laboratory's lower limit of normal 1

Critical caveat: Ferritin is an acute phase reactant. If ferritin is 12-100 μg/dL in the presence of inflammation, malignancy, or liver disease, iron deficiency may still be present. However, if ferritin is >100 μg/dL, iron deficiency is almost certainly excluded 1.

Risk Stratification by Patient Demographics

For Men and Post-Menopausal Women:

You must investigate for gastrointestinal malignancy. The low MCHC with presumed iron deficiency anaemia requires:

1. Upper gastrointestinal endoscopy with small bowel biopsy - to exclude gastric cancer, coeliac disease, and upper GI sources 1
2. Colonoscopy or barium enema - to exclude colonic cancer and polyps 1

This aggressive approach is warranted because asymptomatic gastric and colonic carcinomas commonly present with iron deficiency anaemia, and mild anaemia is equally indicative of serious disease as severe anaemia 1.

For Pre-Menopausal Women:

Menstrual blood loss is the most common cause (5-10% prevalence). However, do not assume menstruation is the cause without proper evaluation 1. If menorrhagia is suspected, consider pictorial blood loss assessment charts (80% sensitivity and specificity) 1.

Treatment Protocol

All patients require oral iron supplementation regardless of whether a cause is identified:

• Ferrous sulphate 200 mg three times daily (or ferrous gluconate/fumarate as alternatives) 1
• Continue for 3 months after correction of anaemia to replenish iron stores 1
• Add ascorbic acid if response is poor, as it enhances iron absorption 1
• Consider parenteral iron only if intolerant to at least two oral preparations 1

When to Pursue Further Investigation

Further gastrointestinal evaluation beyond initial endoscopy and colonoscopy is only warranted if 1:

• Anaemia is transfusion-dependent, or
• There is visible blood loss (e.g., melena)

In transfusion-dependent cases, consider enteroscopy to detect and treat small bowel angiodysplasia 1.

Follow-Up Monitoring

Once hemoglobin and MCHC normalize:

• Monitor every 3 months for 1 year, then again at 2 years 1
• Give additional oral iron if hemoglobin or MCV falls below normal
• Further investigation is only necessary if hemoglobin and MCV cannot be maintained with iron supplementation 1

Reassuringly, iron deficiency does not return in most patients where no cause is initially found after complete investigation 1.

Prognostic Considerations

Recent evidence suggests MCHC has broader clinical implications beyond anemia diagnosis. Lower MCHC values are independently associated with increased mortality risk in various populations 2, 3, though the clinical significance of your specific value of 31.6 g/dL in this context depends on the complete clinical picture and presence of underlying conditions.

Common pitfall: Do not delay investigation in patients with "mild" anemia or assume dietary deficiency without proper workup, as there is no evidence that mild anaemia is less indicative of serious disease than severe anaemia 1.